Resources

Success achieved in reducing trial costs and timelines drives 2026 platform enhancements designed to democratize clinical research analytics.

As we step into 2026, explore the resources that captivated our community in 2025, and more importantly, why they mattered.

This real-world study assessed the effectiveness of bebtelovimab (BEB) versus nirmatrelvir/ritonavir (NR) among outpatients with COVID-19 during the Omicron variant era.

In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, all participants agreed that real-world evidence has the potential to improve regulatory submissions, underscoring the urgency for sponsors to integrate RWE more strategically into their regulatory playbooks.

As 2025 wraps up, the TriNetX team is reflecting on a year of milestones, among them, being named to The Healthcare Technology Report’s Top 50 Healthcare Technology Companies list this November.

Chimeric antigen receptor (CAR) T-cell therapy is among the most promising breakthroughs in modern oncology. By genetically engineering a patient’s T lymphocytes to recognize and destroy cancer cells, CAR T-cell therapy has redefined what is possible in adoptive cellular immunotherapy.

To succeed, biotechs are rethinking how clinical research gets done. RWD, AI, and patient-centric strategies are no longer experimental; they’re emerging as the core toolkit for companies determined to accelerate progress while controlling risk.

The recent ISPOR Europe 2025 conference, held under the inspiring theme ‘Powering Value and Access Through Patient-Centered Collaboration

Real-world data (RWD) plays a crucial role in clinical research and decision-making, yet navigating its complexity remains a significant challenge. RWD typically comes from claims—open or closed—or from electronic health records (EHRs).

I recently had the opportunity to sit down with Danny Levine for an episode of his RARECast podcast  to discuss something I’m deeply passionate about: how real-world data (RWD) is transforming the landscape of rare disease research.

At the recent SCOPE Europe conference, I spoke about a fundamental shift redefining the future of clinical research.

When we think about the future of clinical research, it’s easy to picture gleaming technology, seamless data flows, and a world where trials are faster, smarter, and more inclusive. But let’s be honest. We’re not there yet.